This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset | The Motley Fool
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Source: The Motley Fool
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.